Addex Reclaims the GABAB Keys — With a 2044 Patent Clock Attached

Addex Therapeutics reported half-year 2026 results on 28 September with a message that almost never lands at a company with roughly a $7 million market capitalisation: it got a clinical asset handed back to it, for free, and the paperwork says the exclusivity runs to 2044.

What Changed: Indivior Hands Back the Keys

The catalyst is the termination of the agreement with Indivior. Addex licensed its GABAB positive allosteric modulator chemistry to Indivior in 2018; Indivior selected a candidate, ran it through IND-enabling work — and then, “as part of their announced merger with Supernus” — Tim Dyer, Chief Executive Officer · 2026-09-28, walked away. What came back is not just the licensed compound. Because, as CEO Tim Dyer pointed out, Addex did all the chemistry, biology and patent prosecution itself, the termination also restored the rest of the platform.

In the prior call (December 2025) Indivior was still the good news: “they've successfully completed the IND-enabling studies, and they are currently preparing to move the program forward.” — Timothy Dyer, Chief Financial Officer · 2025-12-04 Nine months later that sentence became the asset description rather than a partner update. Addex now says it holds the broadest GABAB PAM candidate portfolio in the industry, with the substance-use-disorder (SUD) candidate ready to file an IND and a separate, differentiated compound selected for chronic cough.

None of the patents were actually joint patents. None of them were in the hands of Indivior. It was a pure license, and that license has been terminated.

The IP detail is the part most worth flagging. Pressed by H.C. Wainwright's Raghuram Selvaraju on composition-of-matter expiry, Dyer confirmed five patents filed in 2024 — two formerly licensed to Indivior and returned, three never encumbered — and answered the expiry question flatly: “2044. 2044.” — Tim Dyer, Chief Executive Officer · 2026-09-28 A patent run of that length is a new disclosure for this story and the single clearest difference between a pipeline narrative and an investable one.

The Science Benchmarks In Cough

The half-year deck's scientific payload sits in the cough programme. Addex's compound A reduced cough frequency dose-dependently in citric-acid guinea-pig models, showed no tolerance after seven days of subchronic dosing, and — critically — produced “more than 60 % reduction in number of coughs” — Mikhail Kalinichev, Head of Translational Science · 2026-09-28 in the non-human primate model. The company's competitive claim is tolerability: at doses required for maximal efficacy, reference agents (nalbuphine, orvepitant, baclofen, codeine) suppressed respiratory rate, a sedation biomarker, while compound A did not. Dyer frames the prize as an asset with nalbuphine-like efficacy and P2X3-inhibitor-like tolerability. Six months ago his colleague made essentially the same argument to the same analyst, so the thesis is consistent — what's new is that it now sits inside an owned portfolio rather than a partnered one.

Notably, the SUD market framing leans hard on absence: nearly 17% of the U.S. population affected, roughly 90% untreated, and, per Mikhail Kalinichev, no approved drugs for cocaine or psychostimulant use disorders. The competitor list he cites includes a now-fashionable class — GLP-1 inhibitors — which is the one thread connecting Addex's niche to the broader tape. Obesity and GLP-1 names have been advancing in the market's 30-day window, whereas CNS neuropsychiatry is essentially absent from the global top-keyword boards, which are dominated by tariff refunds and AI data-centre compute.

Money, Runway, and the Spin-Out Card

Financially this remains a shoestring. The H1 operating loss was CHF 1.1 million versus CHF 1.3 million a year earlier, cash on the balance sheet was CHF 0.8 million at 30 June, and the equity-method share of Neurosterix's losses added CHF 2.3 million, keeping net loss near CHF 3.4 million. The offsetting event came after the period: “we successfully raised $2.8 million in Q3 through our ATM facility and now have a cash runway through into Q4 of 2027.” — Tim Dyer, Chief Executive Officer · 2026-09-28 That ATM facility raise is the difference between a going-concern question and a run-rate to the next data point.

The other balance-sheet item is the 20% stake in the 2024 Neurosterix spin-out, carried at roughly CHF 2.4 million of non-current assets and, by management's own arithmetic, worth far more than the whole company. On the prior call Dyer put it bluntly: “with a market cap of 8 million today, there seems to be a little bit of a disconnect.” — Timothy Mark Dyer, Chief Executive Officer · 2026-06-25 Neurosterix's lead M4 PAM, NTX-253, is due to complete Phase I in Q4, and a backup has been selected for IND-enabling work. Addex has now floated the same playbook for the returned GABAB assets: with potential partners at the table, “we are also looking at having discussions with investors about a potential spin-out.” — Tim Dyer, Chief Executive Officer · 2026-09-28

Why It Matters

This is a company-unique event, not a sector wave. The global keyword boards show tariff refunds, memory pricing and AI infrastructure; Addex sits nowhere near them. What makes the story legible is the reversal structure: a partner's merger risk (Indivior/Supernus) delivered a de-risked SUD candidate and a de-licensed platform back to a CHF 7-million-market-cap shell whose own prior calls conceded the market wasn't paying for its Neurosterix stake. With no price tape provided for the name, the tell is purely narrative — patents to 2044, cash to Q4 2027, an IND-ready asset and a Q4 Phase I read-across from Neurosterix. The risk is equally plain: everything downstream of that depends on raising money it does not have, and the ATM is currently doing the heavy lifting.